Governance
Uniting our community to improve patient outcomes on the ground
Shared leadership for better and sustainable impact
Only a partnership involving all major stakeholder groups can effectively address the challenges of precision medicine. Based on this belief the participation of founding members representing patient advocacy groups and industry was secured. In addition to this, there is an ongoing effort to seek and add new members from the regulatory, medical, non-profit and academic sectors and beyond, as well as reinforce the participation of the patient community among those who have an interest, expertise in and impact on the different aspects of precision medicine.
The Program is governed by a Board, which represents members and makes the major strategic decisions for the organization.
In order to maintain a patient-centric approach and ensure financial and strategic independence of the Program, Members have decided to cap the participation of industry at maximum 40% on the Board. Equally, a minimum representation of 40% of patients is required. Other stakeholder types such as healthcare professionals are also represented on the Board. The representation requirements may evolve as the program matures to reinforce the balanced and shared decision making approach.
Key principles for collaborative leadership
Balanced representation of stakeholders for transparency, inclusiveness, diversity and credibility. Only a balanced inclusion of all stakeholders, also reflected in decision-making structures and agile operations, deliver results.
The Program is non-competitive and does not exist to promote the interests of any specific organization, their brands or products.
Members and contributors must always work for the interest of the common goal, leaving individual interests at the door.
The FT3 governance
Inclusive and expert advice
The Board
40%
of patient organizations
Maximum
40%
of industry members
Duty of Loyalty
Each board member must put the interests of the Program before their personal and professional interests when acting on behalf of the Program in a decision-making capacity. The Program needs to come first.
Member Organizations
Patient organizations
Pharma & diagnostics companies
HCPs & Medical societies
Payers
HTA bodies
Regulators
Funding and/or participating in kind
Program’s Community
Members and external stakeholders
Agile Operations
Executive Committee (3 seats)
Program Executive Director
Collaborative Program Management
Experts
Medical
Legal
Regulatory
Patient representatives
Ethic
Payer
Communication
Secretariat
Communication
Finance
Advocacy
Reporting & transparency